Compare SMHI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMHI | MXCT |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 180.2M | 160.0M |
| IPO Year | N/A | 2021 |
| Metric | SMHI | MXCT |
|---|---|---|
| Price | $7.18 | $0.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 131.9K | ★ 1.4M |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $245,311,000.00 | $34,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.63 | $0.68 |
| 52 Week High | $7.88 | $4.32 |
| Indicator | SMHI | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 56.90 | 18.09 |
| Support Level | $6.85 | $0.68 |
| Resistance Level | $7.54 | $0.84 |
| Average True Range (ATR) | 0.39 | 0.08 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 70.12 | 13.36 |
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.